Skip to main content
TipRanks
Go Ultimate75% OFF

Balaxi Pharmaceuticals Limited (BALAXI) AI Stock Analysis

0 Followers
IN:BALAXI

Balaxi Pharmaceuticals Limited

(NSE:BALAXI)

Select Model
Rating:44Neutral
Price Target:INR 19.50â–¼(-16.81% Downside)
Action:reiterated
Date:08/30/26

Overall score is weighed down mainly by weak financial performance—especially sustained negative operating/free cash flow and a sharp FY2026 profitability drop—along with bearish technical conditions (price below key moving averages and negative MACD). Valuation provides limited support given the high P/E and no dividend yield data.

Positive Factors
Moderate LeverageModerate leverage gives Balaxi a relatively stronger financial cushion than a highly debt-funded distributor. The sizable equity base can support ongoing operations and selected expansion while reducing the immediate burden of interest and refinancing obligations.
Negative Factors
Recurring Cash BurnRecurring negative operating and free cash flow shows that reported earnings are not converting reliably into cash. If this pattern persists, Balaxi may have less flexibility to fund growth internally and could face greater dependence on external financing or working-capital support.

Balaxi Pharmaceuticals Limited (BALAXI) vs. iShares MSCI India ETF (INDA)

-60%-50%-40%-30%-20%-10%0%10%IN:BALAXI-34.85%INDA-5.86%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
INR 1.29B
Dividend Yield
―
Average Volume (3M)
36.35K
Price to Earnings (P/E)
37.9
Beta (1Y)
1.09
Revenue Growth
―
EPS Growth
―
Country
India
Employees
500
Sector
General
Sector Strength
55
Industry
Medical - Distribution

Balaxi Pharmaceuticals Limited Business Overview & Revenue Model

Company Description

Balaxi Pharmaceuticals Limited, through its entity Balaxi Ventures Ltd., primarily operates as an international wholesale distributor specializing in pharmaceuticals, various food items, and hardware supplies. The company's corporate base is situated...

Balaxi Pharmaceuticals Limited Financial Statement Overview

Summary

Financials are pressured: profitability deteriorated sharply in FY2026 (net margin ~0.5% vs ~8.7% in FY2025) and revenue was slightly down (-1.3% YoY). While leverage is moderate (debt-to-equity ~0.23), cash flow is a major weakness with negative operating cash flow in FY2025–FY2026 and deeply negative free cash flow, increasing funding risk.

Income Statement

46Neutral

Balance Sheet

68Positive

Cash Flow

22Negative
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue2.73B2.73B2.89B2.41B3.36B2.79B
Gross Profit1.20B1.14B1.27B1.13B1.34B837.91M
EBITDA103.60M74.45M305.64M456.59M603.82M560.20M
Net Income14.17M14.17M250.70M-23.87M459.63M476.58M
Balance Sheet
Total Assets3.37B3.37B3.10B2.58B2.40B1.76B
Cash, Cash Equivalents and Short-Term Investments145.59M145.59M394.00M622.91M282.17M71.93M
Total Debt576.49M576.49M534.25M194.04M133.06M36.38M
Total Liabilities879.53M879.53M786.06M569.79M567.89M633.07M
Stockholders Equity2.49B2.49B2.32B2.01B1.83B1.13B
Cash Flow
Free Cash Flow25.78M-451.69M-589.01M32.97M-89.05M68.00M
Operating Cash Flow149.66M-82.44M-377.82M48.66M60.75M341.44M
Investing Cash Flow-167.16M-207.79M-217.64M-10.46M-105.65M-284.48M
Financing Cash Flow11.99M41.82M366.55M302.54M255.13M-1.63M

Balaxi Pharmaceuticals Limited Technical Analysis

Technical Analysis SentimentPositive
Last Price23.44

Price Trends

50DMA22.39Positive
100DMA23.05Positive
200DMA23.08Positive

Market Momentum

MACD0.20Negative
RSI63.43Neutral
STOCH75.17Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:BALAXI, the sentiment is Positive. The current price of 23.44 is above the 20-day moving average (MA) of 21.25, above the 50-day MA of 22.39, and above the 200-day MA of 23.08, indicating a bullish trend. The MACD of 0.20 indicates Negative momentum. The RSI at 63.43 is Neutral, neither overbought nor oversold. The STOCH value of 75.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:BALAXI.

Balaxi Pharmaceuticals Limited Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

IN:BALAXI against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IN:PARIN:PAR73OutperformINR 1.46B11.27――9.40%34.12%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
IN:ALPAIN:ALPA54NeutralINR 1.17B33.08――0.46%-83.31%
IN:BALPHARMAIN:BALPHARMA53NeutralINR 1.43B18.27―1.33%18.79%-2.58%
IN:BALAXIIN:BALAXI44NeutralINR 1.29B37.90――――
IN:NATCAPSUQIN:NATCAPSUQ34UnderperformINR 1.63B-6.96――8.84%-285.42%

* General Sector Average

Performance Comparison

-50%0%50%IN:BALAXIIN:ALPAIN:BALPHARMAIN:PARIN:NATCAPSUQIN:BIDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IN:BALAXI and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IN:BALAXIBalaxi Pharmaceuticals Limited23.44-12.48-34.74%
IN:ALPAAlpa Laboratories Limited55.61-24.36-30.46%
IN:BALPHARMABal Pharma Limited90.1011.3014.34%
IN:PARPar Drugs and Chemicals Limited119.0024.8926.45%
IN:NATCAPSUQNatural Capsules Limited156.10-37.30-19.29%
IN:BIBilcare Ltd83.01-5.14-5.83%

Balaxi Pharmaceuticals Limited Corporate Events

Balaxi Pharma Reports Nil Physical Share Transfer Re-Lodgement Requests for September 2026

Oct 6, 2026

Balaxi Pharmaceuticals Limited has submitted a registrar and transfer agent report to the National Stock Exchange of India on the status of re-lodgement requests for transfer of physical shares, as mandated by a SEBI circular issued in January 2026....

Balaxi Pharmaceuticals Closes Trading Window Ahead of September 2026 Results

Sep 27, 2026

Balaxi Pharmaceuticals Limited has announced the closure of its trading window for designated persons and their immediate relatives from October 1, 2026, in line with SEBI’s Prohibition of Insider Trading Regulations and the company’s internal code o...

Balaxi Pharma Shareholders Clear Second Term for Independent Director Akshita Ostwal

Aug 24, 2026

Balaxi Pharmaceuticals Limited has announced that its shareholders approved the re-appointment of Ms. Akshita Ostwal as an Independent Director at the company’s 83rd Annual General Meeting held on 24 August 2026. Her second term on the board will run...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 30, 2026